ACG Appoints New CEO
Dr. Marcus Michel will take over the role from Richard Stedman, who has served as CEO for the past three years, as he transitions to a special advisor role for the company.
ACG, a supplier of pharmaceutical and nutraceutical solutions, announced on Dec. 7, 2020 that it has named Dr. Marcus Michel as its new CEO. Michel will take over the role from Richard Stedman, who has served as CEO for the past three years, as he transitions to a special advisor role for the company.
Michel has more than 25 years of experience in mechanical, process, and plant engineering for the pharmaceutical, chemical, and allied industries and previously held the position of executive vice president for the GEA Pharma Solutions Business at the GEA Group. He has also held leadership roles at Sued-Chemie, Thyssen Krupp Uhde, and Haldor Topsoe.
“We are very excited to welcome Dr. Marcus Michel to the ACG family,” said Karan Singh, managing director, ACG, in the press release.“He is the right person to lead ACG Engineering into the future, given his command of our business and proven ability to drive results. His track record, depth of international experience, and familiarity with the industry will be highly beneficial in ACG’s growth. I also wish to thank, Richard Stedman, who has helped institutionalize many standard systems and processes across the ACG Engineering group.”
Source: ACG
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
